NCT05583955View on ClinicalTrials.gov

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

October 20, 2023

Study Completion Date

November 24, 2023

Conditions
Childhood-Onset Fluency Disorder
Interventions
DRUG

NOE-105

Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained

DRUG

Placebo

Escalating dose levels of matching Placebo will be given

Trial Locations (9)

2100

Noema Investigator site, Brookvale

2109

Noema Investigator site, Sydney

2228

Noema Investigator site, Miranda

32256

Noema Investigator site, Jacksonville

32801

Noema Investigator site, Orlando

38119

Noema Investigator site, Memphis

66210

Noema Investigator site, Overland Park

90706

Noema Investigator site, Bellflower

08009

Noema Investigator site, Berlin

Sponsors

Lead Sponsor

Noema Pharma AG
All Listed Sponsors
lead

Noema Pharma AG

INDUSTRY

NCT05583955 - A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) | Biotech Hunter | Biotech Hunter